Abstract:Rotavirus is a primary pathogen of infantile diarrhea under the age of five. Rotavirus infection is very popular in developed and developing countries, with similar morbidity, but the mortality is higher in developing countries. There has been no effective treatment at present and further improvement in hygiene to control the spread of rotavirus. So developing safe and effective vaccine is the best way for prevention of rotavirus diarrhea, in order to effectively reduce the morbidity and mortality. Although great progress has been achieved in rotavirus vaccine development, there are still many problems (such as the diversity and wide distribution of rotavirus) in the current rotavirus vaccines industry. Therefore, it's of great importance to develop sequentially navel rotavirus vaccine. The research progresses in human RV vaccine, quality control, protective efficiency and safety evaluation are reviewed in this paper for the pathogenic characteristics and the immune mechanism of the rotavirus.
[1] Zhang YL, Zhang H. Vaccinology[M]. Beijing: Science Press, 2004: 1351-1363. (in Chinese) 张延龄,张晖.疫苗学[M].北京:科学出版社,2004:1351-1363. [2] Wang JZ. Vaccine quality control and evaluation[M]. Beijing: People's Medical Press, 2013: 578-593. (in Chinese) 王军志.疫苗的质量控制与评价[M].北京:人民卫生出版社,2013:578-593. [3] Tate J, Burton A, Boschi-Pinto C, et al. WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2012, 12(2): 136-141. doi:10.1016/S1473-3099(11)70253-5 [4] Tilson L, Jit M, Schmitz S, et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland[J]. Vaccine, 2011, 29(43): 7463-7473. doi:10.1016/j.vaccine. 2011.07.056 [5] Aidelsburger P, Grabein K, Bohm K, et al. Cost-effectiveness of childhood rotavirus vaccination in Germany[J]. Vaccine, 2014, 32(17): 1964-1974. doi:10.1016/j.vaccine.2014.01.061 [6] Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine[J]. N Engl J Med, 2006, 354(1): 23-33. doi:10.1056/NEJMoa052664 [7] Lewis K, Jiang B, Gentsch J, et al. Rotavirus vaccines[J]. Hum Vaccine, 2011, 7(12): 1282-1290. doi:10.1016/S0140-6736(06)68815-6 [8] Cotes-Cantillo K, Paternina-Caicedo A, Coronell-Rodr guez W, et al. Effectiveness of the monovalent rotavirus vaccine in Colombia: A case-control study[J]. Vaccine, 2014, 32(25): 3035-3040. doi:10.1016/j.vaccine.2014.03.064 [9] Paul A, Babji S, Sowmyanarayanan T, et al. Human and bovine rotavirus strain antigens for evaluation of immunogenicity in a randomized, double-blind, placebo-controlled trial of a single dose live attenuated tetravalent, bovine-human-reassortant, oral rotavirus vaccine in Indian adults[J]. Vaccine, 2014, 32(25): 3094-3100. doi:10.1016/j.vaccine.2014.03.013 [10] Mandile MG, Esteban LE, Arg elles MH, et al. Surveillance of group A Rotavirus in Buenos Aires 2008-2011, long lasting circulation of G2P [4]strains possibly linked to massive monovalent vaccination in the region[J]. J Clin Virol, 2014, 60(3): 282-289. doi:10.1016/j.jcv.2014.04.022 [11] Al Awaidy ST, Gebremeskel BG, Al Obeidani I, et al. Cost effectiveness of a pentavalent rotavirus vaccine in Oman[J]. BMC Infect Dis, 2014, 14(1): 334-343. doi:10.1186/1471-2334-14-334 [12] Krishnarajah G, Landsman-Blumberg P, Eynullayeva E. Rotavirus vaccination compliance and completion in a Medicaid infant population[J]. Vaccine, 2015, 33(3): 479-486. doi:10.1016/j.vaccine.2014.06.059 [13] Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children< 5 years of age, 2009-2011[J]. Clin Infect Dis, 2013, 57(1): 13-20. doi:10.1093/cid/cit164 [14] Glass RI, Parashar UD. The promise of new rotavirus vaccines[J]. N Engl J Med, 2006, 354(1): 75-77. doi:10.1056/NEJMe058285 [15] Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development[J]. Vaccine, 2012, 31(1): 58-83. doi:10.1016/j.vaccine.2012.10.083 [16] Garcea RL, Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules[J]. Curr Opin Biotechnol, 2004, 15(6): 513-517. doi:10.1016/j.copbio.2004.10.002 [17] Rodriguez-Limas WA, Sekar K, Tyo KE. Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development[J]. Curr Opin Biotechnol, 2013, 24(6): 1089-1093. doi:10.1016/j.copbio.2013.02.008 [18] Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition[J]. Methods, 2006, 40(1): 60-65. doi:10.1016/j.ymeth.2006.07.018 [19] Ludwig C, Wagner R. Virus-like particles universal molecular toolboxes[J]. Curr Opin Biotechnol, 2007, 18(6): 537-545. doi:10.1016/j.copbio.2007.10.013 [20] Vicente T, Rold o A, Peixoto C, et al. Large-scale production and purification of VLP-based vaccines[J]. J Invertebr Pathol, 2011, 107: S42-S48. doi:10.1016/j.jip.2011.05.004 [21] Rybicki EP. Plant-made vaccines for humans and animals[J]. Plant Biotechnol J, 2010, 8(5): 620-637. doi:10.1111/j.1467-7652.2010.00507.x [22] Stoger E, Fischer R, Moloney M, et al. Plant molecular pharming for the treatment of chronic and infectious diseases[J]. Annu Rev Plant Biol, 2014, 65: 743-768. doi:10.1146/annurev-arplant-050213-035850 [23] Aswathi PB, Bhanja SK, Yadav AS, et al. Plant based edible vaccines against poultry diseases: a review[J]. Adv Anim Vet Sci, 2014, 2(5): 305-311. doi:10.14737/journal.aavs/2014/2.5.305.311 [24] Penney CA, Thomas DR, Deen SS, et al. Plant-made vaccines in support of the Millennium Development Goals[J]. Plant Cell Rep, 2011, 30(5): 789-798. doi:10.1007/s00299-010-0995-5 [25] Hern ndez M, Rosas G, Cervantes J, et al. Transgenic plants: a 5-year update on oral antipathogen vaccine development[J]. Expert Rev Vaccines, 2014, 13(12): 1523-1536. doi:10.1586/14760584.2014.953064 [26] Ahmad P, Ashraf M, Younis M, et al. Role of transgenic plants in agriculture and biopharming[J]. Biotechnol Adv, 2012, 30(3): 524-540. doi:10.1016/j.biotechadv.2011.09.006 [27] Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond[J]. Hum Vaccin, 2011, 7(3): 313-321. doi:10.4161/hv.7.3.14207 [28] Buttery JP, Lambert SB, Grimwood K, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule[J]. Pediatr Infect Dis J, 2011, 30(1): S25-S29. doi:10.1097/INF.0b013e3181fefdee [29] Patel M, Glass R, Jiang B, et al. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy[J]. J Infect Dis, 2013: 1-36. doi:10.1093/infdis/jit166 [30] Premkumar P, Lopman B, Ramani S, et al. Association of serum antibodies with protection against rotavirus infection and disease in South Indian children[J]. Vaccine, 2014, 32: A55-A61. doi:10.1016/j.vaccine.2014.04.077 [31] Steele AD, Madhi SA, Louw CE, et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa[J]. Pediatr Infect Dis J, 2011, 30(2): 125-130. doi:10.1097/INF.0b013e3181f42db9 [32] Clements-Mann ML, Dudas R, Hoshino Y, et al. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants[J]. Vaccine, 2001, 19(32): 4676-4684. doi:10.1016/S0264-410X(01)00242-0 [33] Bayard V, DeAntonio R, Contreras R, et al. Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama[J]. Int J Infect Dis, 2012, 16(2): e94-e98. doi:10.1016/j.ijid.2011.09.003 [34] Patel MM, L pez-Collada VR, Bulh es MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil[J]. N Engl J Med, 2011, 364(24): 2283-2292. doi:10.1056/NEJMoa1012952 [35] Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants[J]. JAMA, 2012, 307(6): 598-604. doi:10.1001/jama.2012.97 [36] Buttery J, Danchin M, Lee K, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia[J]. Vaccine, 2011, 29(16): 3061-3066. doi:10.1016/j.vaccine.2011.01.088 [37] Haber P, Patel M, Pan Y, et al. Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012[J]. Pediatrics, 2013, 131(6): 1042-1049. doi:10.1542/peds.2012-2554 [38] Carlin JB, Macartney KK, Lee KJ, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's national immunization program[J]. Clin Infect Dis, 2013, 57(10): 1427-1434. doi:10.1093/cid/cit520 [39] Kumar D, Beach NM, Meng XJ, et al. Use of PCR-based assays for the detection of the adventitious agent porcine circovirus type 1 (PCV1) in vaccines, and for confirming the identity of cell substrates and viruses used in vaccine production[J]. J Virol Methods, 2012, 179(1): 201-211. doi:10.1016/j.jviromet.2011.10.017 [40] Ichihara MY, Rodrigues LC, Teles Santos CA, et al. Effectiveness of rotavirus vaccine against hospitalized rotavirus diarrhea: A case-control study[J]. Vaccine, 2014, 32(23): 2740-2747. doi:10.1016/j.vaccine.2014.01.007 [41] Payne DC, Baggs J, Zerr DM, et al. Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children[J]. Clin Infect Dis, 2014, 58(2): 173-177. doi:10.1093/cid/cit671 [42] Patel MM, Haber P, Baggs J, et al. Intussusception and rotavirus vaccination: a review of the available evidence[J]. Expert Rev Vaccine, 2009: 1555-1564. doi:10.1586/erv.09.106